Agenus announced strong three-year Phase 1b data for its colorectal cancer drug combination, showing durable survival benefits. Concurrently, the company secured up to $340 million in private placement funding to advance this combination into a pivotal Phase 3 trial, leading to a significant stock surge.
Agenus's stock surged over 111% following the release of compelling three-year Phase 1b data for its botensilimab plus balstilimab combination in refractory metastatic colorectal cancer, demonstrating a median overall survival significantly exceeding historical benchmarks. This positive clinical update was coupled with a successful private placement, raising up to $340 million, which is crucial for funding the planned registrational Phase 3 ROBBIN trial in earlier-stage colon cancer. This strategic shift, including discontinuing financial support for the BATTMAN Phase 3 study, indicates a focused approach on the most promising asset. The short-term implication is a massive positive re-rating for AGEN, while the long-term opportunity hinges on the success of the Phase 3 trial, which is expected to provide an operating runway through 2031. Traders should note the significant capital infusion de-risks the company's near-term operations and validates its strategic direction.